Humana’s suit is based on allegations by the U.S. Department of Justice last year that Regeneron gave a patient-assistance charity kickbacks to boost sales of Eylea, which treats age-related macular degeneration. That case is ongoing in Boston’s federal court.
Humana accused Regeneron of inflating the drug’s price from $1,500 a dose to $1,950 by partnering with the charity, the Chronic Disease Foundation, to cover patients’ cost-sharing obligations for Eylea but not for its competitor. The arrangement boosted Eylea sales at the
The post Humana sues Regeneron over pricing of popular macular degeneration drug first appeared on New York Metropolitan Magazine.